givinostat

Givinostat reduces adverse cardiac remodeling regulating fibroblasts activation

Cardiovascular diseases (CVDs) are a major burden on the healthcare system: indeed, over two million new cases are
diagnosed every year worldwide. Unfortunately, important drawbacks for the treatment of these patients derive from
our current inability to stop the structural alterations that lead to heart failure, the common endpoint of many CVDs. In
this scenario, a better understanding of the role of epigenetics – hereditable changes of chromatin that do not alter

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma